John Evans compensation by year
Beam Therapeutics Summary Compensation Table · all 7 fiscal years held| Component | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Salary | $472,500 | $529,271 | $590,105 | $650,000 | $685,000 | $715,750 | $755,000 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $5,552,775 | $3,223,125 | $1,722,375 | $2,560,600 | $1,513,575 |
| Option awards | $1,368,453 | $0 | $7,336,628 | $5,163,300 | $3,423,499 | $2,615,021 | $2,876,754 |
| Non-equity incentive | $367,813 | $367,813 | $421,925 | $448,500 | $431,550 | $515,340 | $662,513 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $1,034 | $9,684 | $10,542 | $11,820 | $17,675 | $2,920 | $10,684 |
| Total | $2,209,800 | $906,768 | $13,911,975 | $9,496,745 | $6,280,099 | $6,409,631 | $5,818,525 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Beam Therapeutics Inc. DEF 14A filed April 17, 2026, accession 0001193125-26-161512, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Beam Therapeutics Inc. filed document, accession 0001193125-26-161512. Every figure is read from that document and cited to the page and table it appears in. Filed April 17, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 77,500 | $2,148,300 | — |
| RSU | 58,125 | $1,611,225 | — |
| RSU | 28,125 | $779,625 | — |
| RSU | 14,063 | $389,826 | — |
| Option | 2,344 | — | $69.21 |
| Option | 30,469 | — | $43.45 |
| Option | 80,730 | — | $24.40 |
| Option | 119,480 | — | $25.92 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Beam Therapeutics Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
16 Form 4 lines since the FY2025 proxy (filed April 17, 2026)current to 2026-11-06 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-10-16 | Sale | 10b5-1 | 25,000 | $23.98 | 1,047,205 |
| 2026-10-16 | Exercise or conversion derivative | 10b5-1 | 25,000 | $0.00 | 155,804 |
| 2026-10-16 | Exercise or conversion | 10b5-1 | 25,000 | $1.03 | 1,072,205 |
| 2026-10-15 | Exercise or conversion derivative | 10b5-1 | 25,000 | $0.00 | 180,804 |
| 2026-10-15 | Sale | 10b5-1 | 25,000 | $23.57 | 1,047,205 |
| 2026-10-15 | Exercise or conversion | 10b5-1 | 25,000 | $1.03 | 1,072,205 |
| 2026-06-30 | Exercise or conversion | 10b5-1 | 25,000 | $1.03 | 1,072,205 |
| 2026-06-30 | Sale | 10b5-1 | 23,100 | $34.26 | 1,049,105 |
The 8 most recent of 16 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments Beam Therapeutics discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control and involuntary termination | $1,132,500 | $5,412,064 | $53,009 | $7,333,698 |
| Change in control, no termination | $0 | $3,459,117 | $0 | $3,459,117 |
| Involuntary termination without cause | $755,000 | $2,052,147 | $35,339 | $3,333,237 |
Per the Potential Payments Upon Termination or Change in Control table in Beam Therapeutics Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Beam Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| John Evans · this page | Chief Executive Officer | $5,818,525 |
| Giuseppe Ciaramella | President | $3,160,279 |
| Amy Simon | Chief Medical Officer | $2,802,044 |
| Christine Bellon | Chief Legal Officer and Secretary | $1,967,177 |
| Sravan Emany | Chief Financial Officer | $1,296,528 |
Board service
Beam Therapeutics board · FY2021–FY2025How this board is paid
Company policy: Beam Therapeutics pays directors a $50,000 cash retainer and $385,000 in equity. As stated in Beam Therapeutics's FY2025 proxy.
The full Beam Therapeutics compensation record
free company briefThis page is one person within Beam Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Beam Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Beam Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Beam Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order BEAM
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.